ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

Clinical Trials Approved By NCI

October 31, 2003

Social Networks Influence Decision To Quit Smoking

May 30, 2008

NCI RFA: Tobacco Use Research Centers

December 18, 1998

MSK Investigators Report Sialic Acid Test 95% Accurate; Negative Immunotherapy Results Told

June 13, 1980

Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use

March 28, 2008